M&A Deal of the Quarter: AbbVie gets fifth time lucky in Shire pursuit

The $54 billion acquisition in July summed up many of the key trends in mergers and acquisitions this year

The $54 billion acquisition by US pharmaceuticals company AbbVie of UK-listed rival Shire announced in July summed up many of the key trends in mergers and acquisitions this year.

It was a multibillion-dollar deal. It was cross-border. And it involved a US company doing a deal, at least in part, to minimise its tax bill.

WSJ Logo
Pro Bono or Pro Nono? Law Firms Split on Fulfilling Deals With TrumpExternal link

Pro Bono or Pro Nono? Law Firms Split on Fulfilling Deals With Trump